We are live on ! Find out more
FC

Finepoint Capital Portfolio holdings

AUM $1.95B
1-Year Est. Return 45.61%
This Fund
S&P 500
This Quarter Est. Return
+0.84%
1 Year Est. Return
+45.61%
3 Year Est. Return
+24.83%
5 Year Est. Return
+26.66%
10 Year Est. Return
–
AUM
$1.64B
AUM Growth
+$261M
Cap. Flow
+$274M
Cap. Flow %
16.76%
Top 10 Hldgs %
92.42%
Holding
31
New
5
Increased
12
Reduced
4
Closed
5

Top Buys

Rank Stock Value
1
LLYVK icon
Liberty Live Group Series C
LLYVK
+$51.7M
2
RNAM
Avidity Biosciences
RNAM
+$16.4M
3
XNCR icon
Xencor
XNCR
+$15.2M
4
EYPT icon
EyePoint Inc
EYPT
+$3.76M
5
PRTA icon
Prothena Corp
PRTA
+$3.53M

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$24.9M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$13.9M
3
QXO
QXO Inc
QXO
+$12.9M
4
RVMD icon
Revolution Medicines
RVMD
+$1.1M
5
ARGX icon
argenx
ARGX
+$879K

Sector Composition

Rank Sector Weight
1 Industrials 24.21%
2 Healthcare 16.12%
3 Communication Services 12.58%
4 Energy 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLDI icon
26
Calidi Biotherapeutics
CLDI
$2.3M
$14.4K ﹤0.01%
1,042
– –
ACAD icon
27
Acadia Pharmaceuticals
ACAD
$4.38B
– –
-905,384
Closed -$13.9M
TVTX icon
28
Travere Therapeutics
TVTX
$5.27B
– –
-1,782,267
Closed -$24.9M
IVCPW
29
DELISTED
Swiftmerge Acquisition Corp. Warrants
IVCPW
– –
-490,000
Closed -$39.2K
CDAQW
30
DELISTED
Compass Digital Acquisition Corp. Warrant
CDAQW
– –
-459,906
Closed -$28.1K
CLDI.WS
31
DELISTED
Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00
CLDI.WS
– –
-655,200
Closed -$8.58K
1
2

Similar funds

NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
WPC
Waters Parkerson & Co New Orleans, Louisiana $1.95B AUM 15.9% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $1.96B AUM 43.61% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return

Finepoint Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Finepoint Capital held 31 positions worth $1.64B, up 19% from $1.38B the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Finepoint Capital deployed $274M of net new capital in Q4 2024, opening 5 new positions and adding to 12 existing holdings. Its largest new stake was Liberty Live Group Series C: 812,792 shares worth $55.3M.

By sector, the portfolio is most concentrated in Industrials at 24% of assets, down from 30% a quarter earlier, followed by Healthcare and Communication Services.

On the sell side, the largest reduction was QXO Inc, an estimated $12.9M trimmed.

  • Finepoint Capital's largest Q4 2024 buy was Liberty Live Group Series C: 812,792 shares worth $55.3M.
  • Finepoint Capital added most to EyePoint Inc in Q4 2024, an estimated $3.76M increase.
  • Finepoint Capital's biggest Q4 2024 reduction was QXO Inc, cutting an estimated $12.9M.
  • Finepoint Capital fully exited Travere Therapeutics in Q4 2024, selling an estimated $24.9M.
  • Finepoint Capital's ten largest holdings make up 92% of its $1.64B portfolio in Q4 2024.
  • Finepoint Capital opened 5 new positions and closed 5 in Q4 2024.
  • Finepoint Capital's portfolio value rose 19% quarter-over-quarter to $1.64B.

Based on Finepoint Capital's 13F filing for Q4 2024, filed 13 Feb 2025.